The fairer-sex need to pay attention to this piece of news as it is regarding breast cancer. A study claims that women who consume a few kinds of bone-building drugs used to avert and treat osteoporosis may be at a lesser threat of breast cancer.
The study discovered that women who took bisphosphonate drugs like Fosamax, Boniva and Zomita, for over two years supposedly had almost 40 percent decrease in threat as opposed to those who did not. The shielding consequence was said to be noted only among women who were not overweight.
The manner in which these drugs may avert breast cancer is not yet identified, but numerous research observations may be pertinent.
“This large study provides new evidence that the use of bisphosphonates is associated with a potentially important reduction in breast cancer risk. Obese women may have elevated estrogen levels, so underlying hormones may influence the ability of bisphosphonates to reduce breast cancer risk,” commented, lead author Polly Newcomb, Ph.D., M.P.H., head of the Cancer Prevention Program at Fred Hutchinson Cancer Research Center.
Newcomb remarked, “These drugs may affect cell function and be important in cell growth and death – specifically the death of tumors or even premalignant disease.”
Scientists have discovered that a few types of bisphosphonates may promptly result in tumor apoptosis, slow down angiogenesis and avert tumor-cell adhesion. The study included almost 6,000 Wisconsin women, aged 20 to 69. Apparently, half had been detected with invasive breast cancer and, for assessment reasons, half had not. Supposedly, the women were questioned about their bone health, their history of fractures, whether they had been detected with osteoporosis and their history of bisphosphonate use.
Breast cancer threat issues like first-degree family history of the disease, age at first birth, postmenopausal hormone use and body mass index seem to be taken into consideration in the investigation.